Review: Low Selenium Status Linked to Sarcopenia, With Proposed Selenoprotein Mechanisms
This review reports consistent associations between lower selenium biomarkers and poorer muscle outcomes, plus animal and mechanistic evidence; it concludes selenium deficiency is a significant risk factor for sarcopenia, but associations are not proven causes in humans. [1]
Automatic summary · not editorially reviewed
The key findings
Lower selenium biomarkers and dietary selenium intake were significantly associated with poorer muscle outcomes, including decreased grip strength, reduced muscle mass and higher sarcopenia prevalence, in a dose-response pattern. [1]
A clinical study found significantly lower serum selenium levels and glutathione peroxidase activity in patients with sarcopenia. [1]
In animal models, selenium supplementation prevented the decline in muscle selenium content and attenuated muscle atrophy and weakness. [1]
The source at a glance
- Study type / format
- Review (abstract only)
- Population / context
- People in cited epidemiological and clinical studies, plus animal models, as described in the review abstract.
- Summary based on
- Study abstract
- Original publication
- September 18, 2026
Selenium biomarkers and muscle outcomes in epidemiological data
The review describes epidemiological data in which lower serum or plasma selenium, whole blood selenium, the transport protein SELENOP and dietary selenium intake were significantly associated with poorer muscle outcomes. These included decreased grip strength, reduced muscle mass and a higher prevalence of sarcopenia, following a dose-response pattern. A clinical study also found significantly lower serum selenium levels and glutathione peroxidase activity in patients with sarcopenia, linking elevated muscle oxidative stress to depleted selenium status. These are associations; the abstract does not show that low selenium caused the muscle changes.
Supporting source [1]
Animal models and proposed selenoprotein mechanisms
In animal models, the review states, sarcopenia was associated with reduced muscle selenium content, while selenium supplementation prevented this decline and attenuated muscle atrophy and weakness. The proposed protective mechanisms are mediated mainly through specific selenoproteins: GPX4 is described as preserving mitochondrial function and muscle mass by detoxifying lipid peroxides, suppressing inflammation and preventing ferroptosis; SELENOP, secreted by macrophages, as resolving inflammation and supporting muscle stem cell-mediated regeneration; SELENOW, highly expressed in skeletal muscle, as maintaining protein homeostasis via the RAC1-mTOR pathway to counteract atrophy; and SELENOT and SELENON as critical for intracellular calcium homeostasis needed for normal muscle contraction. These are mechanistic proposals and animal findings, not demonstrated human lifespan or muscle benefits.
Supporting source [1]
Review conclusion and abstract-only scope
The review concludes that selenium deficiency constitutes a significant risk factor for sarcopenia and that adequate selenium intake supports a network of selenoproteins combating oxidative stress, regulating inflammation, promoting muscle regeneration and maintaining protein and calcium homeostasis. It frames this as important for nutritional strategies to preserve muscle health in aging populations. This explainer is based only on the abstract; the full text was not reviewed. The abstract does not report study designs, sample sizes, follow-up or effect sizes for the cited studies, so the strength and consistency of the human evidence cannot be judged here.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. The abstract does not report study designs, sample sizes, follow-up or effect sizes, and the human data are associations, not proven causes. Animal and mechanistic findings do not establish human muscle or lifespan benefits.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Ni Q, Wang H, Zhang J, Wang H. · europepmc.org · September 18, 2026